Overview
Emergent BioSolutions Inc., headquartered in Gaithersburg, Maryland, USA, is a global biopharmaceutical company primarily focused on developing and manufacturing vaccines and antibody therapeutics for infectious diseases, as well as opioid overdose treatments. The company plays a pivotal role in public health with key products like BioThrax (Anthrax Vaccine Adsorbed), the only FDA-licensed vaccine against anthrax disease, and Narcan (naloxone HCI) Nasal Spray for emergency treatment of opioid overdose. Emergent also provides specialized products and services to governmental and civilian clients, concentrating on medical countermeasure development and stockpiling for biosecurity purposes. Their involvement in the Biomedical Advanced Research and Development Authority (BARDA)'s initiatives highlights their commitment to addressing biosecurity and public health emergencies.
Basic Stats
The share price of Emergent BioSolutions Inc. as of September 5, 2025 is $7.58 / share. This is a decrease of -8.61% from the prior week. The market cap (or net worth) of Emergent BioSolutions Inc. as of September 5, 2025 is $404.67 MM.
The Factor Analysis chart (below right) shows a view of Emergent BioSolutions Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 404.67 MM |
| EV | 805.17 MM |
| Shares Out. | 53.70 MM |
| Earnings Date | |
| EPS (TTM) | 2.60 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 0.30 MM |
| Short Interest | 9.82 MM |
| Short Float | 18.92 % |
| Days to Cover | 11.31 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -0.59 % |
| Volatility (1 yr) | 0.94 |
| Beta | 2.36 |
| Sharpe Ratio (1 yr) | -0.05 |
| Sortino Ratio (1 yr) | -0.11 |
| PE Ratio | 2.90 |
| Price/Book | 0.75 |
| Price/TBV | 6.02 |
| Book/Market | 1.33 |
| EBIT/EV | 0.24 |
| EBIT(3yr avg)/EV | -0.39 |
| ROA | 0.09 |
| ROE | 0.36 |
| ROIC | 0.12 |
| CROIC | 0.16 |
| OCROIC | 0.14 |
| Implied Volatility | 68.06 % |
| Put/Call OI Ratio | 0.18 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Emergent BioSolutions Inc. is $13.77. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Emergent BioSolutions Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-10 | Benchmark | Buy | Hold | Downgrade |
| 2022-11-09 | Chardan Capital | Buy | Maintains | |
| 2022-09-12 | Cowen & Co. | Market Perform | Maintains | |
| 2022-05-04 | Wells Fargo | Equal-Weight | Maintains | |
| 2022-04-29 | Chardan Capital | Buy | Maintains | |
| 2022-03-10 | Wells Fargo | Equal-Weight | Maintains | |
| 2021-11-10 | Chardan Capital | Buy | Maintains | |
| 2021-11-08 | Benchmark | Buy | Hold | Downgrade |
| 2021-05-05 | Argus Research | Buy | Hold | Downgrade |
| 2021-04-30 | Chardan Capital | Buy | Maintains | |
| 2021-04-07 | Benchmark | Buy | Initiate | |
| 2021-02-24 | Chardan Capital | Neutral | Buy | Upgrade |
| 2021-02-19 | Chardan Capital | Buy | Neutral | Downgrade |
| 2021-01-08 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2020-07-31 | Chardan Capital | Buy | Maintains | |
| 2020-07-17 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-06-08 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-05-06 | Argus Research | Buy | Maintains | |
| 2020-05-01 | Chardan Capital | Buy | Maintains | |
| 2020-05-01 | Cantor Fitzgerald | Overweight | Maintains | |
| 2020-04-30 | Wells Fargo | Overweight | Maintains | |
| 2020-02-25 | Wells Fargo | Overweight | Maintains | |
| 2019-09-12 | Guggenheim | Buy | Initiate | |
| 2019-09-04 | Wells Fargo | Market Perform | Outperform | Upgrade |
| 2018-11-02 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2018-11-02 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2018-09-04 | Chardan Capital | Buy | Buy | Maintains |
| 2018-08-30 | Wells Fargo | Market Perform | Market Perform | Maintains |
| 2018-06-13 | Argus | Buy | Initiate | |
| 2018-06-12 | Cantor Fitzgerald | Overweight | Initiate | |
| 2018-04-25 | Wells Fargo | Outperform | Market Perform | Downgrade |
| 2018-02-27 | Singular Research | Buy | Buy | Maintains |
| 2018-01-24 | Goldman Sachs | Neutral | Initiate | |
| 2016-08-05 | JP Morgan | Overweight | Maintains | |
| 2016-04-15 | Chardan Capital | Buy | Initiate | |
| 2016-03-28 | Singular Research | Buy | Initiate | |
| 2016-02-19 | Wells Fargo | Outperform | Initiate | |
| 2015-08-07 | JP Morgan | Overweight | Maintains | |
| 2015-01-12 | JP Morgan | Overweight | Maintains | |
| 2014-05-15 | Summer Street | Buy | Initiate | |
| 2014-02-17 | JP Morgan | Overweight | Maintains | |
| 2013-04-10 | Janney Capital | Buy | Initiate | |
| 2023-04-10 | Benchmark | Hold | Buy | Upgrade |
| 2023-03-17 | JP Morgan | Neutral | Underweight | Downgrade |
| 2023-05-19 | Benchmark | Buy | Buy | Reiterate |
| 2023-05-31 | Benchmark | Buy | Buy | Reiterate |
| 2023-08-29 | Benchmark | Buy | Hold | Downgrade |
| 2023-11-20 | JP Morgan | Underweight | Reiterate | |
| 2024-04-11 | Benchmark | Buy | Buy | Reiterate |
| 2024-03-07 | Benchmark | Hold | Buy | Upgrade |
| 2024-07-02 | Benchmark | Buy | Buy | Reiterate |
| 2024-07-03 | Benchmark | Buy | Buy | Reiterate |
| 2024-06-24 | Benchmark | Buy | Buy | Reiterate |
| 2024-06-21 | Benchmark | Buy | Buy | Reiterate |
| 2024-06-20 | Benchmark | Buy | Buy | Maintains |
| 2024-12-30 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-08-09 | Benchmark | Buy | Buy | Reiterate |
| 2024-08-22 | Rodman & Renshaw | Buy | Initiate | |
| 2024-08-16 | Benchmark | Buy | Buy | Reiterate |
| 2025-01-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-07 | Benchmark | Buy | Buy | Maintains |
| 2025-01-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-13 | Rodman & Renshaw | Buy | Buy | Reiterate |
| 2025-03-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
